PDCD1 and acute myeloblastic leukemia with maturation: Because of the uncertainty regarding the superior clinical efficacy and the high incidence of severe adverse events compared to that with PD-1 monotherapy, PD-1 plus CTLA-4 is not necessarily the standard of care, and PD-1 monotherapy is still frequently used as the first-line treatment for advanced AM in Japan.